Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurological, Metabolic, and Oncological Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for DDC drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DDC Recombinant Protein (WT & Mutant) – High purity (>95%), Endotoxin <1 EU/µg, Sequence Verified. PLP cofactor binding site preserved. | View DDC Products |
| Gene Delivery | DDC Promise-ORF / Lentivirus – Full-length ORF for stable cell line construction and rescue experiments. | View DDC Products |
| Benchmark Ab | Anti-DDC (Sequence Verified Clone) – Recombinant monoclonal for WB/IHC/ELISA positive control. | View DDC Products |
| Validator | DDC siRNA Set – Validated knockdown efficiency for specificity controls. | View DDC Products |
| Related Target: TH | Tyrosine Hydroxylase – Upstream rate-limiting enzyme in catecholamine synthesis; synergistic pathway target. | View TH Products |
| Related Target: VMAT2 | Vesicular Monoamine Transporter 2 – Downstream packaging of synthesized monoamines. | View VMAT2 Products |
| Related Target: MAOB | Monoamine Oxidase B – Downstream dopamine metabolic enzyme; combination therapy relevance. | View MAOB Products |
| Related Target: DRD2 | Dopamine Receptor D2 – Downstream signaling target for functional synergy studies. | View DRD2 Products |
| Related Target: COMT | Catechol-O-Methyltransferase – Parallel dopamine pathway enzyme for comparative inhibition studies. | View COMT Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzyme Activity & Kinetics (including PLP cofactor incorporation) | Native conformation preserved; HEK293-expressed DDC with intact PLP-binding Lys residue; >95% purity verified by SDS-PAGE and Mass Spec. |
| Ortholog & Species Cross-reactivity (Human/Cyno/Mouse/Rat) | Cross-species recombinant DDC proteins available; Sequence Verified, >95% purity, Endotoxin controlled. |
| Selectivity vs Homologous PLP Enzymes (GAD1, HDC, TPH1/2) | Homolog panel for counter-screening; Sequence Verified for off-target liability assessment. |
| Pathogenic Mutant Validation (AADC deficiency models) | Custom mutant library capability (e.g., R285W, S250F); Sequence Verified, Endotoxin <1 EU/µg. |
| Reliable Controls & Cell Assay False Positives | Sequence-verified benchmark antibodies and siRNA included for assay standardization and knockdown validation. |
| Gene Therapy Vector Titration & Transduction Efficiency | DDC ORF lentivirus with verified copy number; suitable for transduction efficiency standardization in patient-derived lines. |
Live DDC R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The DDC therapeutic landscape is bifurcated between established peripheral inhibition in Parkinson's disease and emerging curative gene therapy for AADC deficiency. First-generation AAV-delivered therapies (e.g., eladocagene exuparvovec by PTC Therapeutics) have demonstrated clinical efficacy in pediatric populations, establishing a precedent for direct striatal AAV2-DDC delivery. The next wave of R&D is targeting optimized enzyme variants, novel small-molecule allosteric modulators, and DDC-driven oncology pathways—specifically in neuroendocrine prostate cancer (NEPC), neuroendocrine tumors (NETs), and solid tumors undergoing neuroendocrine transdifferentiation. In oncology, DDC inhibition represents a metabolic vulnerability requiring sophisticated substrate competition assays. The convergence of enzyme replacement therapy and metabolic oncology is creating dual demand for DDC reagents: ultra-pure enzymatic standards for inhibitor screening and high-titer viral vectors for transduction efficiency validation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV2-DDC) | PTC Therapeutics, Abeona, Voyager, Academic Consortia | AADC Deficiency, Parkinson's Disease | Expression validation & rescue assays (Need Lentivirus ORF, mutant proteins for comparison) |
| Small Molecule Inhibitor | AbbVie, Neurocrine, Novartis, Crinetics, Legacy (Merck, Roche) | Parkinson's Disease (peripheral inhibition), Neuroendocrine Tumors | Binding & selectivity assays (Need high-purity WT/mutant DDC, homolog panel) |
| Targeted Protein Degradation (PROTAC) | Preclinical Biotech | Neuroendocrine Tumors (NEPC) | Degradation assays (Need specific siRNA, high-purity intracellular proteins) |
| Enzyme Replacement / Biologic | Preclinical Academic Groups | AADC Deficiency, Parkinson's Disease (Adjunct) | Activity assay & stability validation (Need mass-spec verified protein with PLP) |
| Prodrug Activation | Various Academic | Solid Tumors | Cell-based conversion assay (Need stable DDC-expressing cell lines) |